Karyopharm Therapeutics (KPTI) Competitors $5.97 -0.30 (-4.78%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. OGI, LYEL, SCPH, FDMT, ACRS, PRQR, RAPT, GLSI, NKTX, and KRROShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Organigram (OGI), Lyell Immunopharma (LYEL), scPharmaceuticals (SCPH), 4D Molecular Therapeutics (FDMT), Aclaris Therapeutics (ACRS), ProQR Therapeutics (PRQR), RAPT Therapeutics (RAPT), Greenwich LifeSciences (GLSI), Nkarta (NKTX), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Organigram Lyell Immunopharma scPharmaceuticals 4D Molecular Therapeutics Aclaris Therapeutics ProQR Therapeutics RAPT Therapeutics Greenwich LifeSciences Nkarta Korro Bio Organigram (NASDAQ:OGI) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Does the media prefer OGI or KPTI? In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Organigram. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 2 mentions for Organigram. Organigram's average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.33 indicating that Organigram is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organigram 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer OGI or KPTI? Karyopharm Therapeutics has a consensus target price of $57.50, indicating a potential upside of 874.58%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Organigram.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, OGI or KPTI? Organigram has higher revenue and earnings than Karyopharm Therapeutics. Organigram is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganigram$166.12M0.86-$33.39M-$0.38-2.99Karyopharm Therapeutics$145.24M0.35-$143.10M-$15.29-0.39 Does the MarketBeat Community favor OGI or KPTI? Karyopharm Therapeutics received 343 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 72.42% of users gave Karyopharm Therapeutics an outperform vote while only 70.71% of users gave Organigram an outperform vote. CompanyUnderperformOutperformOrganigramOutperform Votes19870.71% Underperform Votes8229.29% Karyopharm TherapeuticsOutperform Votes54172.42% Underperform Votes20627.58% Which has more volatility and risk, OGI or KPTI? Organigram has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Do insiders and institutionals hold more shares of OGI or KPTI? 34.6% of Organigram shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 0.1% of Organigram shares are held by insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is OGI or KPTI more profitable? Organigram has a net margin of -31.69% compared to Karyopharm Therapeutics' net margin of -52.62%. Karyopharm Therapeutics' return on equity of 0.00% beat Organigram's return on equity.Company Net Margins Return on Equity Return on Assets Organigram-31.69% -8.59% -6.54% Karyopharm Therapeutics -52.62%N/A -39.58% SummaryOrganigram beats Karyopharm Therapeutics on 9 of the 17 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.56M$6.57B$5.40B$7.68BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-5.787.0922.2118.29Price / Sales0.35263.59392.81105.26Price / CashN/A65.6738.2034.62Price / Book-4.016.396.774.22Net Income-$143.10M$142.49M$3.21B$247.51M7 Day Performance19.19%7.35%4.84%5.54%1 Month Performance-9.37%-8.25%-6.33%-4.23%1 Year Performance-63.91%-1.81%16.11%4.29% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.2096 of 5 stars$5.97-4.8%$57.50+863.1%-61.7%$51.16M$145.24M-5.85380News CoverageOGIOrganigram0.1808 of 5 stars$1.04+1.0%N/A-44.6%$131.31M$166.12M-2.74860News CoverageLYELLyell Immunopharma3.3909 of 5 stars$0.44+1.4%$1.00+124.9%-80.4%$131.26M$61,000.00-0.56270SCPHscPharmaceuticals3.8654 of 5 stars$2.58+11.2%$14.00+442.6%-43.6%$129.73M$36.33M-1.3630Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.8171 of 5 stars$2.78+5.7%$26.71+860.9%-86.2%$128.72M$37,000.00-0.98120Positive NewsACRSAclaris Therapeutics2.625 of 5 stars$1.18+2.6%$11.67+888.7%-2.5%$127.34M$18.72M-2.27100News CoveragePositive NewsPRQRProQR Therapeutics2.4455 of 5 stars$1.18+5.4%$9.50+705.1%-27.7%$124.15M$18.91M-3.69180Gap UpRAPTRAPT Therapeutics3.4398 of 5 stars$0.93+7.2%$4.00+332.0%-89.2%$122.24M$1.53M-0.3380GLSIGreenwich LifeSciences1.7555 of 5 stars$9.28-5.9%$38.00+309.5%-25.0%$121.99MN/A-11.603Analyst ForecastAnalyst RevisionNews CoveragePositive NewsGap UpHigh Trading VolumeNKTXNkarta2.8674 of 5 stars$1.70+7.9%$14.86+773.9%-71.2%$120.63MN/A-0.90140Short Interest ↓Gap UpKRROKorro Bio1.2909 of 5 stars$12.84-0.5%$136.33+961.8%-73.6%$120.56M$2.27M-1.3770Positive NewsGap Up Related Companies and Tools Related Companies Organigram Competitors Lyell Immunopharma Competitors scPharmaceuticals Competitors 4D Molecular Therapeutics Competitors Aclaris Therapeutics Competitors ProQR Therapeutics Competitors RAPT Therapeutics Competitors Greenwich LifeSciences Competitors Nkarta Competitors Korro Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KPTI Stock Free KPTI Stock Alerts